Deep

Nov 19, 2019

Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy

Jun 18, 2019

FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

Nov 12, 2018

Torque Presents Preclinical Data for Deep IL-15 Primed T Cells, Deep IL-12 Primed T Cells, and for the Slipstream(TM) Process for Manufacturing These First-in-Class, Multi-Target Cellular Immunotherapies

Nov 02, 2018

Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO

Nov 01, 2018

CNote Hits a High Note, Celebrates Multi-Milestone Year

Oct 09, 2018

Torque Builds Out Management Team with Immunology, Clinical Development, and Manufacturing Leadership

Aug 01, 2018

Torque Announces Proprietary Slipstream(TM) Platform for High-Efficiency Manufacturing of Deep-Primed T-Cell Therapies

Jul 25, 2018

Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board

Apr 10, 2018

Torque Expands Leadership Team with Appointment of Thomas Andresen, PhD, as Chief Scientific Officer